NeuroSense Therapeutics (NRSN) 6-K/A NeuroSense Announces Second Quarter 2022 Financial Results and Provides Business Update

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K/A

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of January 2023

Commission File Number: 001-41084

NeuroSense Therapeutics Ltd.

(Translation of registrant’s name into English)

11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9-799-6183
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

This Form 6-K/A amends the Form 6-K submitted to the Securities and Exchange Commission by NeuroSense Therapeutics Ltd. (the “Company”) on August 31, 2022 (the “Original 6-K”), which inadvertently did not include the Company’s financial results for the second quarter ended June 30, 2022 in XBRL format.

Attached hereto and incorporated by reference herein are Exhibits 99.1, 99.2 and 99.3 that were included in the Original 6-K as well as the Company’s financial results for the second quarter ended June 30, 2022 in XBRL format.

This Report on Form 6-K/A (including, in Exhibit 99.1, only the text under the headings “Financial Summary” and “Forward-Looking Statements”, Exhibit 99.2 and Exhibit 99.3) is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-262480) and Form F-1 (File No. 333-260338), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit Index

Exhibit No.	Description
99.1	Press Release, dated August 31, 2022
99.2	Condensed Interim Unaudited Financial Statements as of June 30, 2022
99.3	Operating and Financial Review and Prospects as of June 30, 2022
101.INS	Inline XBRL Instance Document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document.
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NeuroSense Therapeutics Ltd.
Date: January 19, 2023	By:	/s/ Alon Ben-Noon
		Alon Ben-Noon
		Chief Executive Officer

2